TY - JOUR T1 - The Influence of Time-Limited Immunity on a COVID-19 Epidemic: A Simulation Study JF - medRxiv DO - 10.1101/2020.06.28.20142141 SP - 2020.06.28.20142141 AU - Robert J. Kosinski Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/29/2020.06.28.20142141.abstract N2 - A series of spreadsheet simulations using SEIS, SEIR, and SEIRS models showed that different durations of effective immunity could have important consequences for the prevalence of an epidemic disease with COVID-19 characteristics. Immunity that lasted four weeks, twelve weeks, six months, one year, and two years was tested with pathogen R0 values of 1.5, 2.3, and 3.0. Shorter durations of immunity resulted in oscillations in disease prevalence. Immunity that lasted from three months to two years produced recurrent disease outbreaks triggered by the expiration of immunity. If immunity “faded out” gradually instead of persisting at full effectiveness to the end of the immune period, the recurrent outbreaks became more frequent. The duration of effective immunity is an important consideration in the epidemiology of a disease like COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study required no funding. It's a simulation study only.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a simulation study only. There are no human subjects, and no IRB approval should be necessary.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe MS is complete as it is. There are no extra data files ER -